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ABSTRACT
Background
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV),
essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF). Subsequent
analysis has shown that constitutive activation of the JAK-STAT signal transduction pathway is
an important pathogenetic event in these patients, and that enzymatic inhibition of JAK2V617F
may be of therapeutic benefit in this context. However, a significant proportion of patients with
ET or MF are JAK2V617F-negative. We hypothesized that activation of the JAK-STAT pathway
might also occur as a consequence of activating mutations in certain hematopoietic-specific
cytokine receptors, including the erythropoietin receptor (EPOR), the thrombopoietin receptor
(MPL), or the granulocyte-colony stimulating factor receptor (GCSFR).
Methods and Findings
DNA sequence analysis of the exons encoding the transmembrane and juxtamembrane
domains of EPOR, MPL, and GCSFR, and comparison with germline DNA derived from buccal
swabs, identified a somatic activating mutation in the transmembrane domain of MPL (W515L)
in 9% (4/45) of JAKV617F-negative MF. Expression of MPLW515L in 32D, UT7, or Ba/F3 cells
conferred cytokine-independent growth and thrombopoietin hypersensitivity, and resulted in
constitutive phosphorylation of JAK2, STAT3, STAT5, AKT, and ERK. Furthermore, a small
molecule JAK kinase inhibitor inhibited MPLW515L-mediated proliferation and JAK-STAT
signaling in vitro. In a murine bone marrow transplant assay, expression of MPLW515L, but not
wild-type MPL, resulted in a fully penetrant myeloproliferative disorder characterized by
marked thrombocytosis (Plt count 1.9–4.0 3 10
12/L), marked splenomegaly due to
extramedullary hematopoiesis, and increased reticulin fibrosis.
Conclusions
Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in
patients with JAK2V617F-negative MF. The bone marrow transplant model of MPLW515L-
mediated myeloproliferative disorders (MPD) exhibits certain features of human MF, including
extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation. Further
analysis of positive and negative regulators of the JAK-STAT pathway is warranted in
JAK2V617F-negative MPD.
The Editors’ Summary of this article follows the references.
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The BCR-ABL negative chronic myeloproliferative disor-
ders (MPD) include polycythemia vera (PV), essential throm-
bocytosis (ET), and myeloﬁbrosis with myeloid metaplasia
(MF) [1]. Although clonal hematopoiesis was observed in these
disorders more than three decades ago, the molecular etiology
of these disorders was not known until recently when several
groups reported a somatic mutation in the JAK2 tyrosine
kinase (JAK2V617F) in most patients with PV and in a subset of
patients with ET and MF [2–6]. Recent estimates using high
sensitivity mutation detection techniques indicate that
JAK2V617F is present in ;95–100% of PV, 60%–70% of ET,
and 50% of MF [7,8]. JAK2V617F is a constitutively active
tyrosine kinase [9] that activates downstream signal trans-
duction pathways and transforms hematopoietic cells to
cytokine-independent growth [4,10], and these cells are
sensitive to a small molecule JAK Inhibitor [2]. In addition,
expressionofJAK2V617Finamurinebonemarrowtransplant
assay results in a MPD most similar to PV [4,11]. These data
indicate that constitutive activation of JAK-STAT signaling by
the mutant JAK2V617F kinase plays a central role in the
pathogenesis of JAK2V617F-positive PV, ET, and MF.
Despite the recent discovery of the JAK2V617F allele,
questions remain regarding the molecular pathogenesis of
PV, ET, and MF. In particular, the mutation(s) responsible for
JAK2V617F-negative ET and MF remain to be identiﬁed.
Although more sensitive techniques can identify JAK2V617F
mutations in a small proportion of clonal cells, we recently
demonstrated that the majority of JAK2V617F-negative ET
and MF patients have clonal granulocytes [7], suggesting that
alternative mutation(s) result in clonal granulopoiesis in this
subset of patients.
We hypothesized that JAK2V617F-negative patients with
MPD might have mutations involving other components of
the JAK-STAT signal transduction pathway that include
cytokine receptors, other JAK family members, or STAT
family members. Screens for additional mutations in other
JAK-STAT signaling intermediates in this clinical context
including JAK1, JAK3, TYK2, STAT3,o rSTAT5 have been
negative [12].
We have recently shown that expression of a homodimeric
type I cytokine receptor, such as the erythropoietin receptor
(EPOR), the thrombopoietin receptor (MPL), or the gran-
ulocyte-colony stimulating factor receptor (GCSFR), is
required for JAK2V617F-mediated transformation of hema-
topoietic cells and for activation of downstream signaling
[10]. These data suggested the possibility that mutations in
the regions of these cytokine receptors that are critical for
receptor dimerization (transmembrane domain) and for
JAK2 binding (juxtamembrane domain) might lead to
activation of JAK-STAT signaling in JAK2V617F-negative
MPD. Indeed, such mutations in the context of EPOR have
been identiﬁed in rare familial cases of polycythemia, though
these have not been reported in acquired MPD. Heretofore,
MPL has been sequenced in a small cohort of patients with
MF and ET, but no mutations were identiﬁed [13], and
multiple groups have reported the absence of EPOR
mutations in small numbers of patients with PV [14,15]. High
throughput DNA sequence analysis and the collection of a
large number of MPD patient samples [2] has enabled
evaluation of a larger series of patients for mutations in
candidate genes, including cytokine receptors. We therefore
investigated patients with JAK2V617F-negative MPD for
somatic activating mutations in EPOR, MPL, or GCSFR.
Methods
Sample Collection
Granulocyte DNA samples and matched normal DNA
samples were collected from patients with PV, ET, and MF
who were enrolled in the Harvard Myeloproliferative
Disorders Study as previously described [2]. Additional
samples from patients with MF were collected on a separate
Dana-Farber Cancer Institute protocol. All subjects provided
informed consent on protocols approved by the Dana-Farber
Cancer Institute Institutional Review Board.
DNA Sequence Analysis and Genotyping for MPLW515L
PCR ampliﬁcation and DNA sequencing of select exons of
MPL, EPOR, and GCSFR was performed using M13-tailed
primers as previously described [2], and speciﬁc primer
sequences are listed in Table S1. Sequence analysis of
bidirectional sequence traces was performed using Mutation
Surveyor version 2.28 (SoftGenetics, State College, Pennsyl-
vania, United States). Candidate mutations were reampliﬁed
and sequenced from original DNA for independent veriﬁca-
tion, and sequence analysis of buccal DNA was performed to
ascertain whether non-synonymous mutations were constitu-
tional or somatic in origin. Identity between granulocyte and
buccal DNA for individual patients was conﬁrmed using eight
informative synonymous single nucleotide polymorphisms.
Genotypic analysis of the HapMap panel of normal patients
was performed using a mass spectrometric assay as previously
described [2].
Expression Vectors and Cell Culture
The MSCV-MPL-Neo and MSCV-MPL-IRES-EGFP retro-
viral vectors were generously provided by W. Tong and H.
Lodish. The MPLW515L mutation was generated using site-
directed mutagenesis (Quickchange-XL, Stratagene, La Jolla,
California, United States) and conﬁrmed by full-length DNA
sequencing. 293T cells were grown in DMEM with 10% fetal
bovine serum (FBS). Transient co-transfection of 293T cells
and generation of retroviral supernatant were performed
using Fugene (Roche, Nutley, New Jersey, United States)
according to manufacturer’s guidelines. 32D and Ba/F3 cells
were grown in RPMI medium 1640 containing 10% FBS and
10% WEHI-3B cell supernatant as a source of IL3. UT7 cells
were grown in IMDM medium supplemented with 10% FBS
and GMCSF (1 ng/mL). 32D cells, Ba/F3 cells, and murine bone
marrow cells were transduced with viral supernatant, and UT7
cells were transduced by electroporation (Amaxa, Gaithers-
burg, Maryland, United States). Cells were then selected in
G418 (1mg/mL). To assess for factor-independent growth and
for thrombopoietin hypersensitivity, cells were ﬁrst washed
three times in PBS, and then 1 3 10
5 viable cells/mL were
resuspended in appropriate cytokine-free media or in media
containing different concentrations of thrombopoietin (Sig-
ma, St. Louis, Missouri, United States) as noted. The number
of viable cells was determined by trypan blue exclusion.
Western Blot Analysis
Cells were collected and lysed in lysis buffer and separated
by electrophoresis as described previously [16]. Nitrocellulose
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e270 1141
MPLW515L Mutation in Myelofibrosismembrane was blocked in TBST/5% milk and incubated with
one of the following antibodies: anti-pSTAT5 (Cell Signaling,
Beverly, Massachusetts, United States), anti-pSTAT3 (Cell
Signaling), anti-pERK (Cell Signaling), anti-pAKT (Cell
Signaling), anti-pTYK2 (Cell Signaling), or anti-pJAK2 (Cell
Signaling). For loading controls, blots were stripped and
reprobed using anti-JAK2 (Santa Cruz Biotechnology, Santa
Cruz, California, United States), anti-TYK2 (Santa Cruz
Biotechnology), anti-STAT5 (Santa Cruz Biotechnology),
anti-STAT3 (Cell Signaling), anti-ERK (Cell Signaling), anti-
AKT (Cell Signaling), and anti-TYK2 (Santa Cruz Biotechnol-
ogy) antibodies as appropriate.
JAK Inhibitor Assays
For cell-proliferation assays, 32D cells stably expressing
FIP1L1-PDGFRA [16] and MPLW515L were grown in RPMI/
10% FBS and then incubated with appropriate concentra-
tions of JAK Inhibitor I (Calbiochem, San Diego, California,
United States) for 72 hours. 32D cells expressing MPLWT
were grown in RPMI/10%FBS/mTPO in the presence of JAK
Inhibitor I. The number of viable cells was determined using
CellTiter 96 Aqueous One Cell Proliferation Assay (Promega,
San Luis Obispo, California, United States). For Western
blotting, cell lines were incubated in the presence of JAK
Inhibitor I for four hours, and phosphorylation of relevant
proteins was assessed as described above.
Murine Bone Marrow Transplant Assay
Themurinebonemarrowtransplant assaywasperformedas
previously described [17]. MSCV retroviral supernatants were
titered by determining the percentage of GFP positive cells 48
hours after infection of Ba/F3 and 32D cells (1 mL supernatant
used to infect 1 3 10
6 cells). MPLWT and MPLW515L
retroviral supernatants were able to reproducibly infect
40%–60%ofBa/F3and32Dcellsasassessedbyﬂowcytometry.
Balb/C donormice were treated with 5-Florouracil (150mg/kg)
seven days prior to bone marrow harvest. Bone marrow cells
were harvested from donor mice, treated with red blood cell
lysis buffer and cultured for 24 hours in transplantation
medium (RPMIþ10% FBSþ6 ng/mL IL-3, 10 ng/mL IL-6, and
10 ng/mL stem-cell factor (SCF)). Cells were treated by spin
infectionwith retroviralsupernatants (1mL supernatantper 4
3 10
6 cells, plus polybrene) and centrifuged at 1,800 g for 90
minutes. The spin infection was repeated 24 hours later. The
cells were then washed and resuspended in Hank’s balanced
salt solution, and injected into lateral tail veins of lethally
irradiated (2 3 4.5 Gy [450 rad]) Balb/C recipient mice
(Taconic, Germantown, New York, United States) at 0.5 to
1.0310
6 cells/mouse. Animals were humanely killed when they
had palpable splenomegaly or were moribund. Animals
transplanted with bone marrow that was transduced with
MPLWT viral supernatant were killed at the time of
manifestation of MPLW515L disease for endpoint analysis.
Mouse Analysis
Peripheral blood was collected from the retro-orbital cavity
using EDTA-treated glass capillary tubes and analyzed by
automated complete and differential blood cell counts and
blood smears (Wright-Giemsa stained). Single-cell suspen-
sions of spleen and bone marrow were prepared by pressing
tissue through a cell strainer, followed by red blood cell lysis.
For histopathology, tissues were ﬁxed in formalin and then
embedded in parafﬁn for histology analysis as previously
described [18].
For ﬂow cytometry, cells were washed in PBS þ 1% bovine
serum albumin and stained with monoclonal antibodies in
PBS þ 1% bovine serum albumin for 30 minutes on ice.
Antibodies used were allophycocyanin–conjugated Gr-1,
B220, Ter119, CD8, cKit; and phycoerythrin–conjugated
Mac-1, CD19, CD71, CD4, CD41 (BD Pharmingen, San Diego,
California, United States). Flow cytometry analysis was
performed on a FACSCalibur instrument (BD Biosciences,
San Jose, California, United States) and analyzed with
CellQuest software (BD Biosciences). Viability was assessed
by incubating cells with 7-AAD (7-amino-actinomycin D) (BD
Pharmingen) for ﬁve minutes prior to ﬂow cytometry. Cells
were gated for viability (using forward/side scatter and 7-
AAD) and GFP positivity, and 10,000 events were analyzed
from this subset for marker expression.
The study protocol was reviewed and approved by the
Boston (Massachusetts, United States) Children’s Hospital
Animal Care and Use Committee.
In Vitro Colony-Forming Assays
Myeloid colony–forming assays were performed in meth-
ylcellulose-based medium (M3434) containing 3U/mL eryth-
ropoietin, 10 ng/mL IL-3, 10 ng/mL IL-6, and 50 ng/mL SCF,
and in M3231 medium containing no additional cytokines, as
per manufacturer’s protocols (StemCell Technologies, Van-
couver, British Columbia, Canada). Cells were plated at 1.5 3
10
4 cells per dish for bone marrow cells and 5 310
4 cells per
dish for spleen cells, in duplicate. Plates were incubated at 37
8C for seven days. Colonies were scored by morphology, and
representative colonies were conﬁrmed by Wright-Giemsa
stained slides of colony cytospins. Graphs represent total
number of colonies counted for three representative mice in
each group, with two plates counted for each mouse.
Megakaryocyte colony–forming assays were performed in
collagen-containing medium (MegaCult-C; StemCell Tech-
nologies) containing TPO, IL-11, IL-3, and IL-6 for seven
days. Slides were ﬁxed and stained for six hours with
acetylcholine iodide (Sigma) as per MegaCult protocol, and
were counterstained with Harris hematoxylin solution (Sig-
ma) as per manufacturer’s protocol.
To assess megakaryocyte ploidy, bone marrow cells were
cultured for four days in RPMI/10% FBS containing 50 ng/mL
mTPO and 10 mg/mL SCF. Cells were collected and stained
with FITC-rat anti-mouse CD41 antibody (BD Biosciences),
followed by 50 ug/mL propidium iodide in 0.1% sodium
citrate buffer with 50 ug/mL RNAase, as previously described
[19]. Data was acquired on a FACSCalibur (BD Biosciences)
and analyzed with CellQuest software.
Results
MPLW515L Mutation in JAK2V617F-Negative MPD
We sequenced the transmembrane and juxtamembrane
domains of EPOR, GCSFR, and MPL in 15 JAK2V617F-
negative MF patients, 16 JAK2V617F-negative patients with
ET, and 4 JAK2V617F-negative PV patients. Although we
found no mutations in EPOR or GCSFR, we identiﬁed a
guanine to thymidine substitution in MPL at nucleotide 1544
which results in a tryptophan to leucine substitution at codon
515 (MPLW515L) in two patients with MF (Figure 1A and 1B).
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MPLW515L Mutation in MyelofibrosisSequencing of 30 additional JAK2V617F-negative MF samples
identiﬁed two additional MPLW515L-positive samples, for a
total frequency of 4/45 (9%) patients. MPLW515L was not
detected in any JAK2V617F-negative ET (n ¼ 50) or PV (n ¼
10) patient samples. Sequence analysis of matched normal
DNA derived from buccal swabs did not identify the
MPLW515L substitution (Figure 1A, upper trace), demon-
strating that MPLW515L is a somatic mutation in hema-
topoietic cells. Sequence analysis of the entire open reading
frame of MPL in all JAK2V617F-negative ET and MF patients
did not reveal additional somatic mutations. To assess the
prevalence of the MPLW515L allele in the general popula-
tion, we genotyped a standard panel of 270 samples collected
by the International HapMap Consortium [20]. All 270
HapMap samples were homozygous for the wild-type
MPLW515 allele.
No signiﬁcant clinical differences were observed between
MPLW515L-positive versus MPLW515L-negative patients
Figure 1. MPLW515L Mutation Is Found in JAK2V617F-Negative MF and Causes Cytokine-Independent Growth in 32D and UT7 Cells, and Constitutively
Activates the JAK-STAT Signaling Pathway
(A) Forward (middle trace) and reverse (lower trace) sequence traces demonstrating a heterozygous guanine to thymine substitution (arrows) presenti n
granulocyte DNA from a patient with MF. The mutation is not present in buccal DNA from the same patient (upper trace).
(B) DNA sequence and protein translation for both the wild-type and mutant MPL alleles. The mutation results in a tryptophan-to-leucine substitutiona t
codon 515.
(C) Upper: 32D cells transduced with MPLW515L exhibit cytokine-independent growth compared with MPLWT (left). Cell lines grown in the presence of
IL3 show equal rates of growth (right). Error bars denote the standard deviation for each sample measured in triplicate. Lower: UT7 cells transformed
with MPLW515L exhibit cytokine-independent growth compared with MPLWT (left). Cell lines grown in the presence of TPO (5 ng/mL) show equal rates
of growth (right). Error bars denote the standard deviation for each sample measured in triplicate.
(D) 32D cells, 32D MPLWT cells, and 32D MPLW515L cells were deprived of cytokines and then analyzed by Western blots, demonstrating
phosphorylation of JAK2, STAT5, STAT3, AKT, and ERK in MPLW515L compared with MPLWT.
DOI: 10.1371/journal.pmed.0030270.g001
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MPLW515L Mutation in Myelofibrosiswith MF with regard to median age at presentation and to
disease duration, though the statistical power of this analysis
was limited by the small number of patients with MF in our
cohort. For all MPLW515L-positive MF patients for which
bone marrow histopathology was available (3/4), marked
megakaryocyte hyperplasia was noted. In addition, two of
the four MPLW515L-positive patients exhibited leukocytosis
and thrombocytosis at the time of disease presentation. One
of the four MPLW515L-positive patients had a rapidly
progressive clinical course, with death two years after initial
presentation from complications related to MF.
Functional Analysis of MPLW515L and Wild-Type MPL
In cell culture assays, expression of MPLW515L, but not
MPLWT, conferred cytokine-independent growth to 32D,
Figure 2. MPLW515L-Expressing Cells Show Hyper-Responsiveness to TPO
(A) 32D MPLWT cells and 32D MPLW515L cells were cultured in triplicate at an initial concentration of 1310
5 cells/mL, in RPMI/10% FBS containing TPO
2 ng/mL, 1 ng/mL, 0.1 ng/mL, 0.01 ng/mL, 0.001 ng/mL, or in the absence of TPO for four days, and then cell numbers were assessed. Error bars denote
the standard deviation for each sample measured in triplicate.
(B) UT7 MPLWT cells and UT7 MPLW515L cells were cultured in triplicate, at an initial concentration of 1 310
5 cells/mL, in IMDM/10% FBS containing
TPO 5 ng/mL, 1 ng/mL, 0.1 ng/mL, 0.01 ng/mL, 0.001ng/mL, or in the absence of TPO for six days, and then cell numbers were assessed. Error bars
denote the standard deviation for each sample measured in triplicate.
(C) 32D MPLWT or 32D MPLW515L cells were deprived of cytokine overnight and then stimulated with TPO 5 ng/mL, 1 ng/mL, 0.1 ng/mL, 0.01 ng/mL, or
without TPO for seven minutes and then analyzed by Western blot for phosphorylation of JAK2 and STAT3, demonstrating increased JAK2/STAT3
phosphorylation in response to TPO in 32D MPLW515L cells as compared with 32D-MPLWT cells.
(D) Phosphorylation of JAK2, TYK2, STAT3, STAT5, AKT, and ERK in response to seven-minute stimulation with TPO (50ng/mL). 32D MPLWT or 32
MPLW515L cells were deprived of cytokine overnight and then stimulated with TPO 50 ng/mL for seven minutes and then analyzed by Western blot for
phosphorylation of JAK2, TYK2, STAT3, STAT5, AKT, and ERK, demonstrating increased phosphorylation of these proteins in response to TPO in 32D
MPLW515L cells as compared with 32D MPLWT cells.
DOI: 10.1371/journal.pmed.0030270.g002
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MPLW515L Mutation in MyelofibrosisUT7, or Ba/F3 cell lines (Figure 1C and unpublished data).
Western blotting demonstrated constitutive phosphorylation
of the JAK/STAT signaling proteins, including JAK2, STAT3,
and STAT5 (Figure 1D). Downstream targets of this pathway
were also activated, with constitutive phosphorylation of p42/
44 ERK and AKT in 32D MPLW515L cells consistent with
activation of the RAS/MAPK and PI3K/AKT pathways (Figure
1D). In addition, expression of MPLW515L in 32D and UT7
cells resulted in hypersensitivity to TPO compared with
MPLWT as assessed by cell growth (Figure 2A and 2B) and by
Western blotting after TPO stimulation (Figure 2C and 2D).
A Murine Model for MPLW515L-Induced
Myeloproliferative Disease
To assess the in vivo effects of the MPLW515L mutant
receptor, we developed a murine model of MPLW515L-
induced myeloproliferative disease. Bone marrow cells were
transduced with MSCV-IRES-EGFP vectors containing
MPLWT or MPLW515L and transplanted into lethally
irradiated Balb/C mice. MPLW515L-transduced animals, but
not MPLWT-transduced animals, developed a short latency
(median latency ¼ 18 days post BMT), fully penetrant, lethal
MPD (Figure 3A) notable for marked thrombocytosis (mean
platelet count ¼ 3.414 3 10
12/L) as well as leukocytosis (mean
WBC ¼ 201 3 10
9/L) (Figure 3B). There was no signiﬁcant
difference in the hematocrit of MPLW515L mice compared
with MPLWT mice. At the time of sacriﬁce, MPLW515L-
expressing mice showed splenomegaly and hepatomegaly
(Figure 3C and 3D), and staining of bone marrow demon-
strated increased reticulin ﬁbrosis in MPLW515L, but not
MPLWT-expressing mice (Figure 3E).
Histopathology analysis was consistent with the presence of
a MPD in MPLW515L-expressing mice, but not in MPLWT-
expressing mice (Figure 4). Examination of peripheral blood
smears from MPLW515L mice revealed marked thrombocy-
tosis and leukocytosis composed of predominantly mature
myeloid elements admixed with occasional to frequent
numbers of nucleated erythroid cells (Figure 4A and 4B).
Compared with MPLWT animals, MPLW515L mice demon-
strated markedly hypercellular bone marrow with a predom-
Figure 3. Bone Marrow Transplant with MPLW515L-Transduced Bone Marrow Causes a Rapid Myeloproliferative Disease
(A) Kaplan-Meier survival plot of Balb/C mice transduced with MPLW515L (n¼9) and MPLWT (n¼6) showing death of all MPLW515L mice between 17
and 32 days post-BMT compared with MPLWT (n ¼ 6), which were sacrificed for endpoint analysis without evidence of disease.
(B) Complete blood counts show leukocytosis and thrombocytosis in MPLW515L BMT model compared with MPLWT. There is no difference in
hematocrits. Standard deviation is indicated.
(C) Spleen weights of MPLW515L and MPLWT mice shows splenomegaly in MPLW515L mice but not in MPLWT mice with average spleen weight equal
to 1,171 mg.
(D) Liver weights of MPLW515L and MPLWT mice shows hepatomegaly in MPLW515L mice but not in MPLWT mice, with average liver weight equal to
2,390 mg (compared with 1,222 mg in MPLWT mice).
(E) Bone marrow shows significantly increased bone marrow fibrosis by reticulin staining at 17 days post-BMT in MPLW515L mice, but not in MPLWT-
expressing mice.
DOI: 10.1371/journal.pmed.0030270.g003
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MPLW515L Mutation in Myelofibrosisinance of maturing myeloid forms and with increased
numbers of atypical and dysplastic megakaryocytes which
could be found in frequent clusters and exhibited emper-
ipolesis of neutrophils in megakaryocyte cytoplasm (Figure
4C and 4D). Spleens from MPLW515L mice revealed
complete effacement of normal splenic architecture (Figure
4E), with a prominent expansion of red pulp composed of an
admixture of maturing myeloid and erythroid elements, and
numerous abnormal megakaryocytes. By comparison, spleens
from MPLWT animals displayed a relative preservation of
normal splenic architecture with only a mild expansion of red
pulp by maturing erythroid elements (Figure 4F and 4H) that
were also noted in small, focal clusters in the livers of these
animals (Figure 4J and 4L). In contrast, extensive extrame-
dullary hematopoiesis was observed in the livers of
MPLW515L animals, which was composed primarily of
maturing erythroid elements with frequent atypical mega-
karyocytes and relatively fewer numbers of mature myeloid
cells (Figure 4I and 4K).
Consistent with the histopathologic ﬁndings, ﬂow cytom-
etry analysis of MPLW515L bone marrow cells demonstrated
an ;4-fold increase in Mac1þ/Gr1þ mature myeloid cells as
compared with bone marrow cells from MPLWT animals
(Figure 5A, upper panels). These ﬁndings were also reﬂected
in the splenocyte populations examined from MPLW515L
animals that revealed a nearly 10-fold increase in Mac1þ/Gr1þ
cells versus MPLWT spleens (Figure 5B, upper panels).
Further analysis of MPLWT and MPLW515L spleen and bone
marrow cells demonstrated a signiﬁcant erythroid population
(Figure 5B, middle panel) in both sets of animals, although a
shift to a more immature erythroid population was observed
in MPLW515L compared with MPLWT mice as reﬂected by
an ;2-fold increase in CD71þ/Ter119- cells (Figure 5A and
5B, middle panels). The marked increase in megakaryocytes
seen in the histopathology of MPLW515L mice was corrobo-
Figure 4. MPLW515L and MPLWT Bone Marrow Transplant Model Histopathology
Histology of MPLW515L-transduced and MPLWT-transduced Balb/C mice showing images of peripheral blood (A and B) and histopathology in
representative sections of bone marrow (C and D), spleen (E–H), and liver (I–L). Peripheral blood smear (B) (6003, Wright-Giemsa) of a representative
MPLWT animal displays an unremarkable white blood cell and platelet count. In contrast, peripheral blood smear (A) (6003, Wright-Giemsa) of a
representative MPLW515L mutant animal reveals marked thrombocytosis and leukocytosis comprising a predominant population of maturing myeloid
cells as well as frequent nucleated erythroid forms. Bone marrow images from MPLWT animals display preserved marrow architecture with maturing
trilineage hematopoiesis (D) (6003, hematoxylin and eosin [H&E]). Comparatively, bone marrow sections from MPLW515L mutant animals demonstrate
marrow elements comprising a prominent population of maturing myeloid cells with increased numbers of megakaryocytes including atypical and
dysplastic forms occurring in frequent clusters (C) (6003, H&E) and showing emperipolesis of neutrophils in megakaryocyte cytoplasm. Spleen sections
from MPLW515L mice display complete effacement of normal splenic architecture (E) (403, H&E) with a marked expansion of red pulp that is composed
of an admixture of maturing myeloid and erythroid elements and numerous numbers of atypical megakaryocytes (G) (6003, H&E) compared with
MPLWT spleens (F and H) (403and 6003, H&E), which display a relative preservation of normal spleen architecture and the presence of only maturing
erythroid forms in the red pulp. Liver images from MPLW515L mice illustrate evidence of extensive extramedullary hematopoiesis in a perivascular and
sinusoidal distribution (I) (1003, H&E) composed predominantly of a population of maturing erythroid elements with frequent large atypical
megakaryocytes and occasional admixed myeloid forms (K) (6003, H&E). In comparison, only small, focal areas of nucleated erythroid cells were
observed in livers from MPLWT animals (J and L) (1003 and 6003, H&E).
DOI: 10.1371/journal.pmed.0030270.g004
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MPLW515L Mutation in Myelofibrosisrated by an ;15-fold increase in the percentage of CD41þ
cells in MPLW515L bone marrow compared with MPLWT
(Figure 5A, bottom panels). Similar increases were observed
in MPLW515L spleen cells compared with MPLWT with an
;30-fold increase in the proportion of CD41þcells observed
in MPLW515L spleen cells compared with MPLWT (Figure
5B, bottom panels). Analysis of B cells demonstrated a
proportionate decrease in B220 positive cells in MPLW515L
bone marrow and spleen (unpublished data). There was no
difference in CD4/CD8þ or c-Kit positive cell populations
between MPLW515L and MPLWT bone marrow and spleen
cells (unpublished data).
MPLW515L Confers a Proliferative Advantage to Bone
Marrow and Spleen Cells
Megakaryocyte colony–forming assays of bone marrow
cells derived from MPLW515L- and MPLWT-expressing
mice demonstrated a similar number of megakaryocyte
colony-forming units, although there was a marked increase
in megakaryocyte colony–forming units formed from spleen
cells from MPLW515L-expressing mice compared with
MPLWT (Figure 6A). In addition, acetylcholinesterase stain-
ing demonstrated MPLW515L megakaryocyte colonies (Fig-
ure 6B, left picture) that were signiﬁcantly larger than
MPLWT megakaryocyte colonies (Figure 6B, right picture).
The difference in megakaryocyte colony growth and
morphology was not explained by a difference in ploidy of
megakaryocyte cells in MPLW515L compared with MPLWT
bone marrow cells (Figure 6C). Perhaps the most striking
ﬁnding was the ability of bone marrow or spleen cells
derived from MPLW515L animals, but not MPLWT, to grow
in methylcellulose culture in the absence of any cytokines
(Figure 6D and 6E). There was also an increase in the
number of myeloid colonies in methylcellulose supple-
mented with cytokines from MPLW515L-expressing spleen
cells (Figure 6E), but not bone marrow cells (Figure 6D),
consistent with a shift in hematopoiesis from the bone
marrow to the spleen in MPLW515L-expressing mice. There
was no difference in the distribution of myeloid colonies
grown from MPLWT- and MPLW515L-expressing mice
(Figure 6D and 6E).
Figure 5. Flow Cytometry Analysis of BM and Spleen in Mice Transduced with MPLW515L and MPLWT
(A) Flow-cytometry analysis of bone marrow cells shows a 4-fold increase in Mac1þ/Gr1þ cells and a shift to a more immature erythroid population.
There is a 15-fold increase in CD41þ cells in bone marrow expressing MPLW515L compared with MPLWT.
(B) Flow-cytometry analysis of spleen cells shows a 10-fold increase in Mac1þ/Gr1þcells in MPLW515L. There is also a shift to a more immature erythroid
population in MPLW515L with a greater percentage of CD71þ/Ter119- cells. CD41þcells are increased 30-fold in MPLW515L spleen cells compared with
MPLWT spleen cells.
DOI: 10.1371/journal.pmed.0030270.g005
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MPLW515L Mutation in MyelofibrosisFigure 6. MPLW515L Increases the Number of Megakaryocyte and Myeloid Colonies in Spleen, without Affecting Megakaryocyte Ploidy, and Causes
Cytokine-Independent Myeloid Colony Growth
(A) Megakaryocyte colony–forming assay in the presence of TPO, IL3, IL11, and IL6 demonstrates similar numbers of megakaryocyte colonies obtained from
MPLW515L-expressing bone marrow and an increase in the number of megakaryocyte colonies from spleen cells compared with MPLWT.
(B) Acetylcholinesterase staining of megakaryocyte colonies derived from bone marrow demonstrates much larger colony size in MPLW515L as compared
with MPLWT megakaryocyte colonies.
(C) Megakaryocyte ploidy analysis shows the same distribution for MPLW515L-expressing cells and MPLWT-expressing cells.
(D and E) Total myeloid colony formation from bone marrow cells (D) and spleen cells (E) demonstrates cytokine-independent colony formation in
MPLW515L bone marrow and spleen. There is no difference in colony distribution between MPLWT- and MPLW515L-expressing cells. Colony counts reflect
only positively identifiable colonies, with thorough megakaryocyte colony analysis done in MegaCult assay (Figure 6A), and thus are excluded from
methylcellulose colony analysis. Colony numbers represent a total of three representative mice per group, in duplicate.
DOI: 10.1371/journal.pmed.0030270.g006
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Induced Proliferation and Signal Transduction
Treatment of 32D MPLW515L or 32D MPLWT cells but not
32D FIP1L1-PDGFRA cells with a small molecule JAK kinase
inhibitor [21] resulted in a dose-dependent inhibition of cell
growth (Figure 7A). Dose-dependent inhibition of phosphor-
ylation of STAT3, ERK, and AKT was observed in 32D
MPLW515L and MPLWT cells but not in 32D FIP1L1-
PDGFRA cells (Figure 7B; unpublished data). These data
indicate that MPLW515L-mediated proliferation and activa-
tion of JAK-STAT signaling is sensitive to inhibition with a
small molecule JAK kinase inhibitor.
Discussion
In this report we describe a somatic mutation in the
transmembrane region of MPL (MPLW515L) in a subset of
JAK2V617F-negative MF. Expression of MPLW515L trans-
forms hematopoietic cells to cytokine-independent prolifer-
ation, and results in constitutive activation of JAK-STAT
signaling. The relevance of this mutation is underscored by its
effect in the murine bone marrow transplant assay, as
expression of MPLW515L induces myeloproliferation char-
acterized by splenomegaly, leukocytosis, marked thrombocy-
tosis, extramedullary hematopoeisis, and myeloﬁbrosis. In
addition, a small-molecule JAK kinase inhibitor inhibits
proliferation of MPLW515L-transformed cells, suggesting
that targeted inhibition of JAK-STAT signaling may be an
effective therapy for both JAK2V617F-positive and
MPLW515L-positive MPD.
Although the constitutively active JAK2V617F mutant
kinase is present in many patients with MPD, there are a
signiﬁcant proportion of MF and ET patients who are
JAK2V617F-negative. We hypothesized that activation of
JAK–STAT signaling in these patients might result from
activating mutations in cytokine receptors, which led to the
discovery of a novel mutation in MPL (MPLW515L)i n
patients with JAK2V617F-negative MF. The mutation is
present in granulocytes but not in non-hematopoietic germ-
line DNA, demonstrating that MPLW515L is a somatic
mutation present in clonally derived hematopoietic cells.
Moreover, the MPLW515L allele was not observed in a panel
of normal individuals, demonstrating that it is not a common
single nucleotide polymorphism. These data provide genetic
evidence that MPLW515L is a pathogenetic mutation in this
subset of JAK2V617F-negative MF.
In contrast to previous reports [13–15], we have identiﬁed a
mutant MPL receptor that results in constitutive activation of
downstream signal transduction pathways. MPL signals via its
association with JAK2 and TYK2, resulting in phosphoryla-
Figure 7. 32D MPLW515L Cells Are Sensitive to JAK Inhibitor I
(A) Dose-dependent inhibition of growth of 32D MPLW515L and 32D MPLWT cells but not 32D FIP1L1-PDGFRA cells with increasing doses of JAK
Inhibitor I.
(B) Reduction in STAT3 phosphorylation in 32D MPLW515L cells but not 32D FIP1L1-PDGFRA cells with increasing doses of JAK Inhibitor I. Cells were
incubated with varying drug concentrations for four hours and then collected for Western blot analysis.
DOI: 10.1371/journal.pmed.0030270.g007
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MPLW515L Mutation in Myelofibrosistion of both MPL and JAK2/TYK2 and consequent activation
of the STAT3, STAT5, ERK/MAPK, and PI3K/AKT signaling
pathways. MPLW515L activates JAK-STAT signal transduc-
tion independently of ligand binding, and, in contrast with
MPLWT, confers cytokine-independent growth to 32D, Ba/F3,
and UT7 cells. Moreover, Western blot analysis shows ligand-
independent phosphorylation of downstream signaling pro-
teins, which may effect both proliferation and differentiation.
Finally, hematopoietic cells that express MPLW515L are
hypersensitive to stimulation with TPO as assessed by cell
proliferation and Western blot analysis, suggesting
MPLW515L-positive hematopoietic progenitors may have a
selective proliferative advantage as compared with wild-type
progenitors in MF patients.
The discovery of this mutation provides a novel mechanism
for activation of signal transduction in hematopoietic malig-
nancies. Somatic mutations in MPL have not previously been
described, though previous genetic and biochemical data
suggest that the cytoplasmic-transmembrane junction (which
includes W515) is important in its activation. These data
include the germline S505N allele in MPL associated with
familialET[22,23],theW515Smutationthathasbeenreported
asaspontaneousmutationinBa/F3cellsstablytransducedwith
MPL[24], and the observation that in vitro deletion of the
RWQFP domain that includes W515 results in MPL activation
[25].ThemechanismofactivationofMPLbytheseallelesisnot
fully understood, and it will be of value to obtain structural
insight into the role of the cytoplasmic transmembrane–
junction region in the regulation of MPL signal transduction.
Expression of MPLW515L in murine bone marrow reca-
pitulated many of the phenotypic characteristics of MF in
humans, including atypical megakaryocytic hyperplasia,
splenomegaly due to extramedullary hematopoiesis, and
thrombocytosis that may be attenuated in humans by splenic
sequestration [26,27]. This is in contrast to murine bone
marrow transplant experiments with constitutively activated
tyrosine kinase alleles evaluated in our laboratory and by
others, including TEL-JAK2, FLT3-ITD, and FIP1L1-PDGFRA
[17,28,29], that each result in a neutrophilic MPD without
involvement of the megakaryocyte lineage. It is of interest
that JAK2V617F, which is associated with ET and MF in
humans, results in polycythemia and leukocytosis, but not
thrombocytosis, in the same murine BMT model [11]. Of note,
absolute leukocytosis in both the JAK2V617F and the
MPLW515L-mediated BMT models is higher than is typically
observed in human PV and MF, respectively. Also,
MPLW515L mice develop rapidly fatal disease. These differ-
ences between the murine model and the human phenotype
are likely accounted for by the retroviral transduction model
of disease, and is similar to what has been observed for the
rapidly fatal BCR-ABL-mediated disease in the murine BMT
model as compared with human CML [30].
MPLW515L-expressing bone marrow and spleen cells
exhibit cytokine-independent colony formation, another
feature of clinical ET and MF. In addition, the MPLW515L
murine bone marrow transplant model shares some pheno-
typic characteristics with other murine models of MF,
including that induced by overexpression of thrombopoietin,
either in transgenic [31] or in bone marrow transplant models
[32,33], and in the transgenic GATA-1
low mouse [34], though
the severity and chronicity of the MF phenotype varies in
these different models, which, unlike the current model, are
not based on somatic disease alleles observed in human MF.
MPLW515L is an attractive target for therapeutic inter-
vention with small molecule inhibitors. Current treatments
for MF include empiric therapies such as hydroxyurea or
interferon, and splenectomy for symptomatic splenomegaly
[26,27]. Allogeneic stem cell transplantation is a viable option
for some patients with MF, but most patients are diagnosed at
an advanced age and are not candidates for stem cell
transplantation. Recent clinical trials with thalidomide
demonstrated modest efﬁcacy in MF, largely by slowing the
rate of ﬁbrosis in these patients rather than by reversal of
ﬁbrosis [35]. Allogeneic BMT data does indicate that erad-
ication of the malignant hematopoietic clone in MF does
result in complete reversal of ﬁbrosis [36], and suggests that
drugs that target mutant alleles such as MPLW515L may be
effective disease-remitting agents. JAK2 inhibitor develop-
ment is well under way as a potential therapeutic strategy for
treating MPD patients with the JAK2V617F allele. Data
presented here indicate that the subset of JAK2V617F-negative
MF patients with the MPLW515L mutation will also be
sensitive to inhibition with small molecule JAK2 inhibitors.
These ﬁndings also suggest that a more expansive genomic
screen for involvement of other components of the JAK-STAT
signal transduction pathway is warranted in MPD patients.
Supporting Information
Table S1. Primer Sequences Used in This Study
Found at DOI: 10.1371/journal.pmed.0030270.st001 (25 KB DOC).
Accession Numbers
The UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼unigene) accession numbers used in this paper are MPL
(Hs.82906 and Mm.4864), EPOR (Hs.127826), and GCSFR (Hs.524517).
Acknowledgments
YP is a Research Training Fellow of the Howard Hughes Medical
Institute. DGG is a Doris Duke Foundation Distinguished Clinical
Scientist and an Investigator of the Howard Hughes Medical Institute.
TRG is an Investigator of the Howard Hughes Medical Institute. TM is
a recipient of a Special Fellow Award from the Leukemia and
Lymphoma Society. MW is a recipient of an American Society of
Clinical Oncology Young Investigator Award. We thank the patients
who participated in this study and Joyce Niblack, JD, for support and
access to the mpdinfo.org (Myeloproliferative Disorders) Web site.
We are indebted to Allison Coburn, Rachel Okabe, and Dana Cullen
for assistance with sample processing and mouse work, to Tarrah
Kirkpatrick and Arnold Gonzales for assistance with the MPD study,
and to Alexis Bywater for technical and administrative assistance.
Author contributions. YP, DGG, and RLL designed the study and
wrote the manuscript. YP, BHL, TM, BLE, and RLL performed
research and analyzed data. BHL and TM contributed to writing the
manuscript. EMD, MG, AC, JJC, and MW performed research. SM
provided technical assistance. IG, DJD, and JJC organized the
collection of samples at Dana-Farber Cancer Institute. GW, SJL,
TRG, and MW contributed to study design.
References
1. Dameshek W (1951) Some speculations on the myeloproliferative syn-
dromes. Blood 6: 372–375.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating
mutation in the tyrosine kinase JAK2 in polycythemia vera, essential
thrombocythemia, and myeloid metaplasia with myeloﬁbrosis. Cancer Cell
7: 387–397.
3. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread
occurrence of the JAK2 V617F mutation in chronic myeloproliferative
disorders. Blood 106: 2162–2168.
4. James C, Ugo V, Le Couedic JP, StaERK J, Delhommeau F, et al. (2005) A
unique clonal JAK2 mutation leading to constitutive signalling causes
polycythaemia vera. Nature 434: 1144–1148.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloprolifer-
ative disorders. Lancet 365: 1054–1061.
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e270 1150
MPLW515L Mutation in Myelofibrosis6. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, et al. (2005) A gain-of-
function mutation of JAK2 in myeloproliferative disorders. N Engl J Med
352: 1779–1790.
7. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, et al. (2006) X-
inactivation based clonality analysis and quantitative JAK2V617F assess-
ment reveals a strong association between clonality and JAK2V617F in PV
but not ET/MMM, and identiﬁes a subset of JAK2V617F negative ET and
MMM patients with clonal hematopoiesis. Blood 107: 4139–41.
8. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, et al. (2005)
V617F mutation in JAK2 is associated with poorer survival in idiopathic
myeloﬁbrosis. Blood 107: 2098–2100.
9. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identiﬁcation of an Acquired
JAK2 Mutation in Polycythemia Vera. J Biol Chem 280: 22788–22792.
10. Lu X, Levine R, Tong W, Wernig G, Pikman Y, et al. (2005) Expression of a
homodimeric type I cytokine receptor is required for JAK2V617F-
mediated transformation. Proc Natl Acad Sci U S A 102: 18962–18967.
11. WernigG,MercherT,OkabeR,LevineRL,LeeBH,etal.(2006)Expressionof
JAK2V617F causes a polycythemia vera-like disease with associated myelo-
ﬁbrosis in a murine bone marrow transplant model. Blood 107: 4274–4281.
12. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, et al. (2005) The
V617F JAK2 mutation is uncommon in cancers and in myeloid malig-
nancies other than the classic myeloproliferative disorders. Blood 106:
2920–2921.
13. Taksin AL, Couedic JP, Dusanter-Fourt I, Masse A, Giraudier S, et al. (1999)
Autonomous megakaryocyte growth in essential thrombocythemia and
idiopathic myeloﬁbrosis is not related to a c-mpl mutation or to an
autocrine stimulation by Mpl-L. Blood 93: 125–139.
14. Le Couedic JP, Mitjavila MT, Villeval JL, Feger F, Gobert S, et al. (1996)
Missense mutation of the erythropoietin receptor is a rare event in human
erythroid malignancies. Blood 87: 1502–1511.
15. Hess G, Rose P, Gamm H, Papadileris S, Huber C, et al. (1994) Molecular
analysis of erythropoietin receptor system in patients with polycythaemia
vera. Br J Haematol 88: 794–802.
16. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A
tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a
therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N
Engl J Med 348: 1201–1214.
17. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, et al. (2002) FLT3
internal tandem duplication mutations associated with human acute
myeloid leukemias induce myeloproliferative disease in a murine bone
marrow transplant model. Blood 99: 310–318.
18. Stover EH, Chen J, Lee BH, Cools J, McDowell E, et al. (2005) The small
molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and
FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106: 3206–3213.
19. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, et al. (2005) Loss of
Runx1 perturbs adult hematopoiesis and is associated with a myeloproli-
ferative phenotype. Blood 106: 494–504.
20. (2003) The International HapMap Project. Nature 426: 789–796.
21. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, et al.
(2002) Photochemical preparation of a pyridone containing tetracycle: A
Jak protein kinase inhibitor. Bioorg Med Chem Lett 12: 1219–1223.
22. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, et al. (2004) Familial
essential thrombocythemia associated with a dominant-positive activating
mutation of the c-MPL gene, which encodes for the receptor for
thrombopoietin. Blood 103: 4198–4200.
23. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC (1998) An activating
splice donor mutation in the thrombopoietin gene causes hereditary
thrombocythaemia. Nat Genet 18: 49–52.
24. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H (2002) A novel MPL point
mutation resulting in thrombopoietin-independent activation. Leukemia
16: 1500–1506.
25. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, et al. (2005) An
amphipathic motif at the transmembrane-cytoplasmic junction prevents
autonomousactivationofthethrombopoietinreceptor.Blood107:1864–1871.
26. Tefferi A (2005) Pathogenesis of myeloﬁbrosis with myeloid metaplasia. J
Clin Oncol 23: 8520–8530.
27. Tefferi A (2000) Myeloﬁbrosis with myeloid metaplasia. N Engl J Med 342:
1255–1265.
28. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, et al. (2000) STAT5 is
essential for the myelo- and lymphoproliferative disease induced by TEL/
JAK2. Mol Cell 6: 693–704.
29. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, et al. (2003) PKC412
overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRal-
pha-induced myeloproliferative disease. Cancer Cell 3: 459–469.
30. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic
myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia
chromosome. Science 247: 824–830.
31. Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, et al. (2005)
Transgenic mice overexpressing murine thrombopoietin develop myelo-
ﬁbrosis and osteosclerosis. Leuk Res 29: 761–769.
32. Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, et al. (1997)
High thrombopoietin production by hematopoietic cells induces a fatal
myeloproliferative syndrome in mice. Blood 90: 4369–4383.
33. Yan XQ, Lacey D, Fletcher F, Hartley C, McElroy P, et al. (1995) Chronic
exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-
speciﬁc growth and differentiation of megakaryocytes in mice. Blood 86:
4025–4033.
34. Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, et al. (2002)
Development of myeloﬁbrosis in mice genetically impaired for GATA-1
expression (GATA-1(low) mice). Blood 100: 1123–1132.
35. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, et al. (2004) Low-
dose thalidomide ameliorates cytopenias and splenomegaly in myeloﬁb-
rosis with myeloid metaplasia: A phase II trial. J Clin Oncol 22: 424–431.
36. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, et al. (2003)
Allogeneic hematopoietic stem cell transplantation for myeloﬁbrosis.
Blood 102: 3912–3918.
Editors’ Summary
Background. Myelofibrosis with myeloid metaplasia (MF) is one of a
group of chronic blood disorders, known as chronic myeloproliferative
disorders. These disorders sometimes turn into acute leukemia. The main
abnormality in myelofibrosis is for the bone marrow to become filled
with fibrous (scar) tissue (hence the name myelofibrosis), which stops it
from producing normal blood cells efficiently. In addition, the white
blood cells that remain are abnormal (that is, metaplastic). The clinical
effect of these abnormalities are that patients are anemic (they have low
numbers of red cells), are more likely to get infections because of the
abnormal white cells which cannot fight infections normally, and may
bleed more easily because of a lack of the platelets that help the blood
to clot. Scientists who study this disorder believe that the disease starts
from just one abnormal cell, which divides to replace all the other cells—
that is, all the abnormal cells are part of one clone.
Why Was This Study Done? In two similar diseases, polycythemia vera
(in which the bone marrow produces too many red blood cells) and
essential thrombocytosis (in which the bone marrow produces too many
platelets), and in some patients with MF, scientists have found genetic
changes which seem to trigger these diseases. However, there are some
patients with MF in which no abnormal gene has been found. The
scientists here wanted to look at other genes to see if they could find any
changes that might trigger MF.
What Did the Researchers Do and Find? They decoded the DNA
sequence of three genes that are known to be involved in how blood
cells develop for 45 patients with MF. They looked at DNA from white
blood cells, and also from normal cheek cells for comparison. They found
that in four of the 45 patients the DNA in the bone marrow, but not the
cheek, carried a mutation in a gene for the thrombopoietin receptor
(also called MPL). This gene is necessary for the cells that make platelets
to grow correctly. The mutation was not present in any samples from
patients with diseases related to MF, nor in 270 normal samples. The
mutation that was identified was at position 515 in the MPL gene
sequence, hence the name MPLW515L—the W and the L are the
shorthand way of indicating exactly which change occurred. The change
meant that the gene became abnormally active. The researchers tested
the effect of the abnormal gene by putting it into cells grown in culture
in the laboratory; they found that it made the cells grow more than was
normal. In addition, when cells with the abnormal gene were put into
mice, the mice developed a blood disorder similar to that seen in
humans with MF.
What Do These Findings Mean? It seems likely that the genetic change
t h a th a sb e e ni d e n t i f i e dh e r ei sr e s p o nsible for the MF that develops in some
patients.TheMPLgeneisknowntobepartofapathwayofgenesthatcontrol
how certain blood cells develop. However, it is not yet clear exactly how the
geneticchangefoundherecausesthebloodcellstogrowabnormally,orhow
itcausestheotherclinicaleffectsofMF.Furtherworkwillalsoneedtobedone
to see if it is possible to develop drugs that can act on this gene mutation, or
on the other genes that it affects so as to return the cells to normal.
Additional Information.PleaseaccesstheseWebsites viatheonlineversion
of this summary at http://dx.doi.org/10.1371/journal.pmed.0030270.
  MedlinePlus, a Web site of the US National Library of Health, has pages of
information on myelofibrosis and related diseases
  The National Cancer Institute, which funds research into many cancers, has
information for patients on myelofibrosis, including information on clinical
trials
  The MPD Foundation has information for patients with myelofibrosis and
related diseases
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